• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用(+)-[11C]二氢丁苯那嗪正电子发射断层扫描术鉴别阿尔茨海默病与路易体痴呆和帕金森病。

Differentiating Alzheimer's disease from dementia with Lewy bodies and Parkinson's disease with (+)-[11C]dihydrotetrabenazine positron emission tomography.

作者信息

Koeppe Robert A, Gilman Sid, Junck Larry, Wernette Kris, Frey Kirk A

机构信息

Division of Nuclear Medicine, Department of Radiology, The University of Michigan, Ann Arbor, MI, USA.

出版信息

Alzheimers Dement. 2008 Jan;4(1 Suppl 1):S67-76. doi: 10.1016/j.jalz.2007.11.016.

DOI:10.1016/j.jalz.2007.11.016
PMID:18632004
Abstract

BACKGROUND

Several progressive neurologic disorders begin with cognitive decline or parkinsonism, notably Alzheimer's disease (AD), Parkinson's disease (PD), and dementia with Lewy bodies (DLB). We used positron emission tomography (PET) in attempts to differentiate these disorders.

METHODS

We performed PET with (+)-[11C]dihydrotetrabenazine ([11C]DTBZ) to examine blood-to-brain ligand transport (K(1)) and striatal monoaminergic presynaptic binding (distribution volume [DV]) in 25 DLB, 30 PD, and 25 AD patients and 57 elderly controls (NC).

RESULTS

[11C]DTBZ DV was decreased significantly in caudate nucleus, anterior putamen, and posterior putamen in DLB and PD compared with AD and NC. DLB and PD groups showed an anterior-to-posterior gradient of binding loss relative to NC, least in caudate nucleus and largest in posterior putamen. The gradient was significantly steeper in PD than DLB. Both PD and DLB showed significantly greater interhemispheric striatal binding asymmetry than NC, and PD had greater asymmetry than DLB. Cerebral cortical [11C]DTBZ K(1) was decreased diffusely by 4% to 8% in PD. Larger K(1) deficits occurred in AD and DLB temporoparietal and prefrontal association cortices and posterior cingulate cortex. Greater reduction of K(1) occurred in occipital cortex in DLB than AD. Receiver operating characteristic curve analyses distinguished DLB from AD more effectively on the basis of striatal DV than occipital K(1) and distinguished DLB from PD more effectively on the basis of cerebral cortical K(1) than striatal DV patterns. Overall, 90% of cases were properly classified by combining these measures.

CONCLUSIONS

PET with [11C]DTBZ can differentiate DLB from both PD and AD in a single neuroimaging study.

摘要

背景

几种进行性神经疾病始于认知功能下降或帕金森综合征,尤其是阿尔茨海默病(AD)、帕金森病(PD)和路易体痴呆(DLB)。我们使用正电子发射断层扫描(PET)来试图区分这些疾病。

方法

我们对25例DLB患者、30例PD患者、25例AD患者和57例老年对照(NC)进行了(+)-[11C]二氢丁苯那嗪([11C]DTBZ)PET检查,以检测血脑配体转运(K(1))和纹状体单胺能突触前结合(分布容积[DV])。

结果

与AD和NC相比,DLB和PD患者尾状核、壳核前部和壳核后部的[11C]DTBZ DV显著降低。与NC相比,DLB和PD组显示出从前往后的结合丧失梯度,在尾状核中最小,在壳核后部最大。PD组的梯度比DLB组显著更陡。PD和DLB组的半球间纹状体结合不对称性均显著高于NC组,且PD组的不对称性大于DLB组。PD患者大脑皮质[11C]DTBZ K(1)弥漫性降低4%至8%。AD和DLB患者颞顶叶和前额叶联合皮质以及后扣带回皮质出现更大的K(1)缺陷。DLB患者枕叶皮质的K(1)降低幅度大于AD患者。受试者工作特征曲线分析显示,基于纹状体DV区分DLB和AD比基于枕叶K(1)更有效,基于大脑皮质K(1)区分DLB和PD比基于纹状体DV模式更有效。总体而言,通过结合这些测量方法,90%的病例得到了正确分类。

结论

在一项单一的神经影像学研究中,使用[11C]DTBZ的PET能够区分DLB与PD和AD。

相似文献

1
Differentiating Alzheimer's disease from dementia with Lewy bodies and Parkinson's disease with (+)-[11C]dihydrotetrabenazine positron emission tomography.使用(+)-[11C]二氢丁苯那嗪正电子发射断层扫描术鉴别阿尔茨海默病与路易体痴呆和帕金森病。
Alzheimers Dement. 2008 Jan;4(1 Suppl 1):S67-76. doi: 10.1016/j.jalz.2007.11.016.
2
Striatal monoamine terminals in Lewy body dementia and Alzheimer's disease.路易体痴呆和阿尔茨海默病中的纹状体单胺能终末
Ann Neurol. 2004 Jun;55(6):774-80. doi: 10.1002/ana.20088.
3
11C-DTBZ and 18F-FDG PET measures in differentiating dementias.11C-二氢麦角苄酯和18F-氟脱氧葡萄糖正电子发射断层显像测量在鉴别痴呆中的应用
J Nucl Med. 2005 Jun;46(6):936-44.
4
The application of statistical parametric mapping to 123I-FP-CIT SPECT in dementia with Lewy bodies, Alzheimer's disease and Parkinson's disease.统计参数映射在路易体痴呆、阿尔茨海默病和帕金森病的123I-FP-CIT单光子发射计算机断层扫描中的应用。
Neuroimage. 2004 Nov;23(3):956-66. doi: 10.1016/j.neuroimage.2004.06.045.
5
In vivo assessment of vesicular monoamine transporter type 2 in dementia with lewy bodies and Alzheimer disease.路易体痴呆和阿尔茨海默病中2型囊泡单胺转运体的体内评估
Arch Neurol. 2011 Jul;68(7):905-12. doi: 10.1001/archneurol.2011.142.
6
Brain 3D-SSP SPECT analysis in dementia with Lewy bodies, Parkinson's disease with and without dementia, and Alzheimer's disease.路易体痴呆、伴或不伴痴呆的帕金森病以及阿尔茨海默病的脑三维单光子发射计算机断层扫描(3D-SSP SPECT)分析
Clin Neurol Neurosurg. 2005 Aug;107(5):396-403. doi: 10.1016/j.clineuro.2004.12.005. Epub 2005 Jan 19.
7
Differential diagnosis in Alzheimer's disease and dementia with Lewy bodies via VMAT2 and amyloid imaging.通过 VMAT2 和淀粉样蛋白成像对阿尔茨海默病和路易体痴呆进行鉴别诊断。
Neurodegener Dis. 2012;10(1-4):161-5. doi: 10.1159/000334535. Epub 2012 Jan 17.
8
Dementia with Lewy bodies can be well-differentiated from Alzheimer's disease by measurement of brain acetylcholinesterase activity-a [11C]MP4A PET study.通过测量脑乙酰胆碱酯酶活性,路易体痴呆可与阿尔茨海默病很好地区分——一项[11C]MP4A正电子发射断层扫描研究。
Int J Geriatr Psychiatry. 2015 Nov;30(11):1105-13. doi: 10.1002/gps.4338. Epub 2015 Aug 17.
9
PET imaging of amyloid with Florbetapir F 18 and PET imaging of dopamine degeneration with 18F-AV-133 (florbenazine) in patients with Alzheimer's disease and Lewy body disorders.使用氟代贝他吡F 18对阿尔茨海默病和路易体疾病患者进行淀粉样蛋白的正电子发射断层扫描(PET)成像,以及使用18F-AV-133(氟苯嗪)对多巴胺变性进行PET成像。
BMC Neurol. 2014 Apr 9;14:79. doi: 10.1186/1471-2377-14-79.
10
Distinct FP-CIT PET patterns of Alzheimer's disease with parkinsonism and dementia with Lewy bodies.阿尔茨海默病伴帕金森病和路易体痴呆的 FP-CIT PET 不同模式。
Eur J Nucl Med Mol Imaging. 2019 Jul;46(8):1652-1660. doi: 10.1007/s00259-019-04315-6. Epub 2019 Apr 12.

引用本文的文献

1
Targeting dopamine transporter to ameliorate cognitive deficits in Alzheimer's disease.靶向多巴胺转运体以改善阿尔茨海默病的认知缺陷。
Front Cell Neurosci. 2023 Nov 13;17:1292858. doi: 10.3389/fncel.2023.1292858. eCollection 2023.
2
A Scoping Review of Cognitive Training in Neurodegenerative Diseases via Computerized and Virtual Reality Tools: What We Know So Far.通过计算机化和虚拟现实工具对神经退行性疾病认知训练的范围综述:目前我们所了解的情况。
Brain Sci. 2021 Apr 21;11(5):528. doi: 10.3390/brainsci11050528.
3
Innovative Molecular Imaging for Clinical Research, Therapeutic Stratification, and Nosography in Neuroscience.
用于神经科学临床研究、治疗分层及疾病分类的创新分子成像
Front Med (Lausanne). 2019 Nov 27;6:268. doi: 10.3389/fmed.2019.00268. eCollection 2019.
4
Lewy Body Disease: Clinical and Pathological "Overlap Syndrome" Between Synucleinopathies (Parkinson Disease) and Tauopathies (Alzheimer Disease).路易体病:泛素相关疾病(帕金森病)与 Tau 相关疾病(阿尔茨海默病)之间的临床和病理学“重叠综合征”。
Curr Neurol Neurosci Rep. 2018 Apr 8;18(5):24. doi: 10.1007/s11910-018-0835-5.
5
Molecular Imaging and Updated Diagnostic Criteria in Lewy Body Dementias.路易体痴呆中的分子成像与更新的诊断标准
Curr Neurol Neurosci Rep. 2017 Aug 14;17(10):73. doi: 10.1007/s11910-017-0789-z.
6
Recent progress of imaging agents for Parkinson's disease.帕金森病成像剂的最新进展。
Curr Neuropharmacol. 2014 Dec;12(6):551-63. doi: 10.2174/1570159X13666141204221238.
7
Imaging Amyloidopathy in Parkinson Disease and Parkinsonian Dementia Syndromes.帕金森病和帕金森痴呆综合征中的淀粉样变成像
Clin Transl Imaging. 2015 Feb 1;3(1):57-64. doi: 10.1007/s40336-015-0104-4.
8
UPDATE ON DEMENTIA WITH LEWY BODIES.路易体痴呆的最新情况
Curr Transl Geriatr Exp Gerontol Rep. 2013 Sep 1;2(3):196-204. doi: 10.1007/s13670-013-0053-6.
9
Structural and functional imaging in parkinsonian syndromes.帕金森综合征的结构和功能成像
Radiographics. 2014 Sep-Oct;34(5):1273-92. doi: 10.1148/rg.345140009.
10
NIH workshop on clinical translation of molecular imaging probes and technology--meeting report.美国国立卫生研究院分子成像探针与技术临床转化研讨会——会议报告
Mol Imaging Biol. 2014 Oct;16(5):595-604. doi: 10.1007/s11307-014-0746-z.